
News|Videos|January 30, 2024
Nivolumab Plus Ipilimumab Versus Sunitinib For First-Line Treatment of Advanced Renal Cell Carcinoma: Long-Term Follow-Up Data From the Phase 3 CheckMate 214 Trial
Author(s)Nizar M. Tannir, MD, FACP
Nizar Tannir, MD, FACP, presents extended follow-up data assessing the combination of nivolumab and ipilimumab compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma (RCC).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5


































